News and Events Tag: 2020

Twoxar Pharmaceuticals Inc., of Mountain View, Calif., said that two leads for the potential treatment of systemic lupus erythematosus, TXR-711 and TXR-712, demonstrated significant efficacy and excellent tolerability in preclinical studies. The data were accepted at the 12th European Lupus Congress and published in Lupus Science & Medicine.
This week we are celebrating the release of the 250th version of our drug discovery software platform! I am so incredibly proud of the improvements our software team is constantly pushing out; it is the foundation that supports twoXAR’s dedication to rapidly identifying treatments for patients in need.